GILD Gilead Sciences Inc

Price (delayed)

$62.96

Market cap

$78.91B

P/E Ratio

19.08

Dividend/share

$2.88

EPS

$3.3

Enterprise value

$100.39B

Gilead Sciences, Inc. /ˈɡɪliəd/, is an American biopharmaceutical company headquartered in Foster City, California that researches, develops and commercializes drugs. The company focuses primarily on antiviral drugs used in the ...

Highlights
Gilead Sciences's debt has decreased by 13% YoY
GILD's revenue is up by 3.3% year-on-year
GILD's P/E is 71% below its 5-year quarterly average of 66.0 but 24% above its last 4 quarters average of 15.4
GILD's EPS is down by 20% year-on-year and by 8% since the previous quarter
The company's net income fell by 20% YoY and by 8% QoQ

Key stats

What are the main financial stats of GILD
Market
Shares outstanding
1.25B
Market cap
$78.91B
Enterprise value
$100.39B
Valuations
Price to earnings (P/E)
19.08
Price to book (P/B)
3.9
Price to sales (P/S)
2.87
EV/EBIT
15.34
EV/EBITDA
11.6
EV/Sales
3.65
Earnings
Revenue
$27.52B
EBIT
$6.54B
EBITDA
$8.65B
Free cash flow
$9.42B
Per share
EPS
$3.3
Free cash flow per share
$7.5
Book value per share
$16.13
Revenue per share
$21.91
TBVPS
$19.64
Balance sheet
Total assets
$62.87B
Total liabilities
$42.66B
Debt
$26.22B
Equity
$20.24B
Working capital
$3.96B
Liquidity
Debt to equity
1.3
Current ratio
1.43
Quick ratio
1.06
Net debt/EBITDA
2.48
Margins
EBITDA margin
31.4%
Gross margin
75.6%
Net margin
15%
Operating margin
25.5%
Efficiency
Return on assets
6.3%
Return on equity
20%
Return on invested capital
17.6%
Return on capital employed
12.2%
Return on sales
23.8%
Dividend
Dividend yield
4.57%
DPS
$2.88
Payout ratio
87.3%

GILD stock price

How has the Gilead Sciences stock price performed over time
Intraday
0.82%
1 week
3.06%
1 month
0.99%
1 year
-11.17%
YTD
-13.29%
QTD
1.86%

Financial performance

How have Gilead Sciences's revenue and profit performed over time
Revenue
$27.52B
Gross profit
$20.8B
Operating income
$7.01B
Net income
$4.14B
Gross margin
75.6%
Net margin
15%
The operating margin has contracted by 31% YoY and by 3% from the previous quarter
The operating income has declined by 28% year-on-year and by 3% since the previous quarter
Gilead Sciences's net margin has decreased by 23% YoY and by 9% QoQ
The company's net income fell by 20% YoY and by 8% QoQ

Growth

What is Gilead Sciences's growth rate over time

Valuation

What is Gilead Sciences stock price valuation
P/E
19.08
P/B
3.9
P/S
2.87
EV/EBIT
15.34
EV/EBITDA
11.6
EV/Sales
3.65
GILD's P/E is 71% below its 5-year quarterly average of 66.0 but 24% above its last 4 quarters average of 15.4
GILD's EPS is down by 20% year-on-year and by 8% since the previous quarter
The stock's price to book (P/B) is 7% less than its 5-year quarterly average of 4.2 and 2.5% less than its last 4 quarters average of 4.0
Gilead Sciences's equity has increased by 2.7% YoY
GILD's price to sales (P/S) is 20% less than its 5-year quarterly average of 3.6 and 4.3% less than its last 4 quarters average of 3.0
GILD's revenue is up by 3.3% year-on-year

Efficiency

How efficient is Gilead Sciences business performance
The company's return on equity fell by 28% YoY and by 9% QoQ
GILD's return on assets is down by 19% year-on-year and by 7% since the previous quarter
GILD's return on sales is down by 18% year-on-year and by 4.8% since the previous quarter
Gilead Sciences's ROIC has decreased by 2.8% from the previous quarter

Dividends

What is GILD's dividend history
DPS
$2.88
Dividend yield
4.57%
Payout ratio
87.3%
Recent dividends

Financial health

How did Gilead Sciences financials performed over time
GILD's total assets is 47% higher than its total liabilities
The total liabilities has contracted by 12% YoY
GILD's total assets is down by 8% YoY
Gilead Sciences's debt is 30% higher than its equity
The company's debt to equity fell by 15% YoY
Gilead Sciences's debt has decreased by 13% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.